Blog

Designing better medicines using AI and big data

By its own definition, South By Southwest dedicates itself to helping creatives achieve their goals, and proves that the most unexpected discoveries happen when diverse topics and people come together.

And this is what brought our Benevolent Team to Texas - to share our collective vision of using the power of technology to solve something that truly matters to the world. For us this means tackling the most challenging and devastating diseases that currently have no cure, and we believe our efforts can and will change outcomes for patients.

In this video live from SXSW last month, our team of scientists and AI experts presented a ‘behind the scenes’ introduction to show how our latest advancements in machine learning and AI can better understand the underlying causes of diseases, and redefine the way in which new medicines are discovered and brought to patients.

At SXSW we used the example of Glioblastoma Multiforme, a very aggressive, currently incurable and most common form of brain cancer. We demonstrated something different and a little unconventional - the creative approach of how our team of BenevolentAI scientists, AI experts, engineers and chemists come together to try and solve such a complicated disease.

AI helps us uncover relationships between diseases and symptoms, drugs and their effect, the patients who respond to treatments and so much more. Relationships that would previously not have been uncovered due to the overwhelming volume of biomedical information and the inherent complexity of biology, diseases and the human body.

It’s too early to say if there will be an effective treatment for Glioblastoma any time soon. But every day, we improve our platform and increase the likelihood of finding a treatment. And we hope to return to SXSW to demonstrate the progress we are making on this devastating disease.

More Posts

You Might Also Like

Blog
Tech Nation Visa: the gateway to world-leading UK tech jobs
Drawing attention to the Tech Nation Visa, a great initiative that enables the brightest international talent to live and work in the UK.
Feb 19, 2021
News
BenevolentAI announces first patient dosed in its Atopic Dermatitis clinical trial
A molecule designed and developed by BenevolentAI to treat mild to moderate Atopic Dermatitis has entered clinical trials.
Feb 11, 2021
News
BenevolentAI and AstraZeneca achieve collaboration milestone with novel AI-generated chronic kidney disease target
BenevolentAI and AstraZeneca hit collaboration milestone with an AI-generated CKD target from the partnership entering AstraZeneca’s portfolio.
Jan 27, 2021
News
ACTT-2 trial results published in the New England Journal of Medicine validate baricitinib’s efficacy in combination with remdesivir in hospitalised COVID-19 patients
Peer-reviewed data from the ACTT-2 further validate BenevolentAI’s hypothesis for baricitinib as a potential COVID-19 treatment.
Jan 15, 2021
Blog
Joanna Shields speaks at the Global Partnership on Artificial Intelligence
BenevolentAI CEO Joanna Shields opened the final plenary of the Global Partnership on Artificial Intelligence (GPAI) summit with a powerful message on the future of AI.
Dec 11, 2020
Blog
BenevolentAI wins Innovation Award at 2020 Scrip Awards
BenevolentAI wins the Innovation Award at the prestigious 2020 Scrip Awards for our work in artificial intelligence applied drug discovery.
Dec 11, 2020